ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1120

Long-Term Echocardiographic Findings in Idiopathic Recurrent Pericarditis Patients Treated with Anakinra

Zeynep Toker Dincer1, Damla Raimoglu2, Erkin Yilmaz3, Ayten Dag1, Sejla Karup4, Melike Melikoglu1 and Serdal Ugurlu5, 1Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 2Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Cardiology, Istanbul, Turkey, 3Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Istanbul, Turkey, 4Cerrahpasa Faculty of Medicine, Istanbul, Turkey, 5Istanbul University-Cerrahpasa, Istanbul, Turkey

Meeting: ACR Convergence 2024

Keywords: Autoinflammatory diseases, Biologicals, Ultrasound

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 17, 2024

Title: Miscellaneous Rheumatic & Inflammatory Diseases Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Idiopathic recurrent pericarditis (IRP) is characterized by recurrent pericarditis attacks, and autoinflammatory pattern has been highlighted due to similarities in both clinical features and treatment responses. The most feared complication of recurrent pericarditis is constrictive pericarditis (CP), with a very low risk in IRP patients on conventional treatment but higher in those who are corticosteroid-dependent and colchicine-resistant.
Persistent pericardial effusion in patients with clinical remission is another concern, with a small proportion of those under conventional treatment showing mild, ongoing effusion on echocardiography. However, data on long-term echocardiographic findings in IRP patients who are resistant to conventional treatment and require Anakinra therapy are limited.
In this study, we aimed to evaluate pericardial thickness, pericardial echogenicity, pericardial effusion, and the presence of tamponade and CP using echocardiography in IRP patients treated with Anakinra.

Methods: We recruited 15 patients with IRP who had been treated with Anakinra at our autoinflammatory clinic between 2011 and 2023 and had been in clinical and laboratory remission for the past three months. All patients had echocardiographic data available within the last three months. Demographic, clinical, and treatment data were extracted from patient records. Echocardiographic data were compared with age- and gender-matched healthy controls (HC). Additionally, patients were stratified into two groups: those who had discontinued Anakinra treatment and those who were continuing the treatment. Furthermore, to understand the persistence of pericardial effusion despite clinical remission, patients with pericardial effusion were compared with those without effusion.

Results: Fifteen IRP patients and 20 HC were included in the study. The demographic, clinical, and treatment data of the patients are shown in Table 1. Echocardiographic examination revealed that pericardial thickness and hyperechogenicity were significantly higher in patients than HC (p< 0.001). Mild pericardial effusion (< 10 mm) persisted in 60% of the patients. No patients had pericardial tamponade or constrictive pericarditis. However, tricuspid inflow for respiratory variation was significantly higher in the patient group than in HC (p=0.018) (Table 2). No significant differences were observed in the variables between patients continuing Anakinra treatment and those who had discontinued it, and there were also no differences between patients with pericardial effusion and those without effusion (Table 3).

Conclusion: We found that IRP patients treated with Anakinra and in remission had greater pericardial thickness and hyperechogenicity than HC, and most still had mild effusion. It is unclear whether these findings are sequelae of past pericarditis or signs of subclinical ongoing inflammation. Although tamponade and constrictive pericarditis were not detected, the significantly higher tricuspid inflow for respiratory variation, an early sign of tamponade, compared to controls is noteworthy. Therefore, these patients should be closely monitored to identify and manage potential complications.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: Z. Toker Dincer: None; D. Raimoglu: None; E. Yilmaz: None; A. Dag: None; S. Karup: None; M. Melikoglu: None; S. Ugurlu: None.

To cite this abstract in AMA style:

Toker Dincer Z, Raimoglu D, Yilmaz E, Dag A, Karup S, Melikoglu M, Ugurlu S. Long-Term Echocardiographic Findings in Idiopathic Recurrent Pericarditis Patients Treated with Anakinra [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/long-term-echocardiographic-findings-in-idiopathic-recurrent-pericarditis-patients-treated-with-anakinra/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/long-term-echocardiographic-findings-in-idiopathic-recurrent-pericarditis-patients-treated-with-anakinra/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology